Nasdaq:US$9.61 (+0.03) | HKEX:HK$15.54 (-0.82) | AIM:£1.59 (+0.03)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 3 Jun 2014

ASCO 2014: First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors